Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  signal transduction inhibitor
Trial Status:  Active
Results 1-25 of 3555 for your search:
Start Over
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRI-724-101, NCT01302405
A Study of LY2940680 in Japanese Participants With Advanced Cancers
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14895, I4J-MC-HHBH, NCT01919398
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-17302, NCT01842646
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: AMC-089, NCI-2014-00638, U01CA121947, NCT02137564
A Synthetic Hedgehog Pathway Inhibitor for Keratocystic Odontogenic Tumors (KCOT)
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: ML28859, NCT02366312
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1130, NA_00047491, NCT01431794
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: Ribavirin=005, NCT02073838
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-206, NCT01579929
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1013, NA_00036883, NCT01088815
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML28897, NCT02091141
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 21 at diagnosis
Sponsor: Other
Protocol IDs: SJMB12, NCI-2013-01125, NCT01878617
A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1371012, 2014-001345-24, NCT02367456
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OIC-1UO-C001, NCT01100463
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A8641020, 2014-002286-30, NCT02299635
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CC#11455, NCT01383538
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMR 200066-010, NCT01668017
PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-1558.cc, NCI-2013-00824, NCT01841333
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1371003, 2012-000684-24, NCT01546038
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: ML28485, NCT01700049
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and ove
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1371005, NCT02038777
Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201412087, NCT02277093
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-003516-31, NCT01713218
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 72
Sponsor: Other
Protocol IDs: 11-164, NCT01485744
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 18
Sponsor: Other
Protocol IDs: NMTRCPG007, NCT01774253
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJB-TNBC-1-RHEA, 2014-004358-32, NCT02338531
Start Over